Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial

Nicolas Kerckhove, David Tougeron, Côme Lepage, Denis Pezet, Karine Le Malicot, Manon Pelkowski, Bruno Pereira, David Balayssac, Nicolas Kerckhove, David Tougeron, Côme Lepage, Denis Pezet, Karine Le Malicot, Manon Pelkowski, Bruno Pereira, David Balayssac

Abstract

Background: The use of oxaliplatin in digestive tract cancers could induce severe peripheral neuropathy (OIPN) decreasing the quality of life of patients and survivors. There is currently, no univocal treatment for these peripheral neuropathies. Donepezil, a reversible inhibitor of cholinesterase, used to treat Alzheimer's disease and dementia, is reported to have a good safety profile in humans, and preclinical data have provided initial evidence of its effectiveness in diminishing neuropathic symptoms and related comorbidities in OIPN animal models.

Methods: The DONEPEZOX trial will be a proof-of-concept, randomised, triple-blinded, and multicentre study. It will be the first clinical trial evaluating the efficacy and safety of donepezil for the management of OIPN. Adult cancer survivors with OIPN that report sensory neuropathy according to QLQ-CIPN20 sensory score (equivalence of a grade ≥ 2), at least 6 months after the end of an oxaliplatin-based chemotherapy will be included. Eighty patients will be randomly assigned to receive either donepezil or placebo over 16 weeks of treatment. The primary endpoint will be the rate of responders (neuropathic grade decreases according to the QLQ-CIPN20 sensory score) in the donepezil arm. The severity of OIPN will be assessed by the QLQ-CIPN20 sensory scale before and after 16 weeks of treatment. The comparison versus the placebo arm will be a secondary objective. The other secondary endpoints will be tolerance to donepezil, the severity and features of OIPN in each arm before and after treatment, related-comorbidities and quality of life. Fleming's one-stage design will be used for sample size estimation. This design yields a type I error rate of 0.0417 and power of 91% for a responder rate of at least 30% in donepezil arm. A total of 80 randomized patients is planned.

Discussion: This study will allow, in the case of positive results, to initiate a phase 3 randomized and placebo-controlled (primary endpoint) clinical study to assess the therapeutic interest of donepezil to treat OIPN.

Trial registration: NCT05254639 , clincialtrials.gov, Registered 24 February 2022.

Keywords: Anticholinesterase; Chemotherapy-induced peripheral neuropathy; Donepezil; Oxaliplatin; Pain; Study protocol.

Conflict of interest statement

The authors declare that they have no competing interests. MYLAN will not provide donepezil free of charge and will not participate in any stage of the clinical study or analysis of the results.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study Design and evaluations

References

    1. Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D. Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front Pharmacol. 2017;8:86. doi: 10.3389/fphar.2017.00086.
    1. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155:2461–2470. doi: 10.1016/j.pain.2014.09.020.
    1. Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019;19:132. doi: 10.1186/s12885-019-5302-4.
    1. de Carvalho BM, Kosturakis AK, Eng C, Wendelschafer-Crabb G, Kennedy WR, Simone DA, et al. A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. Cancer Res. 2014;74:5955–5962. doi: 10.1158/1538-7445.AM2014-389.
    1. García de Paredes ML, Del Moral González F, Martínez Del Prado P, Martí Ciriquián JL, Enrech Francés S, Cobo Dols M, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients Results of the On study. Ann Oncol Off J Eur Soc Med Oncol. 2011;22:924–30. doi: 10.1093/annonc/mdq449.
    1. Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2005;32:305–311. doi: 10.1188/05.ONF.305-311.
    1. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33:15–49. doi: 10.1053/j.seminoncol.2005.12.010.
    1. Smith EML, Beck SL, Cohen J. The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2008;35:96–102. doi: 10.1188/08.ONF.96-102.
    1. Giraudet F, Selvy M, Kerckhove N, Pereira B, Barreau F, Nguyen D, et al. Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol Head Neck Surg. 2022 doi: 10.1007/s00405-021-07234-1.
    1. Selvy M, Pereira B, Kerckhove N, Busserolles J, Farsi F, Guastella V, et al. Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists’ professional practices. Support Care Cancer. 2021 doi: 10.1007/s00520-020-05928-6.
    1. Park SB, Lin CSY, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist. 2011;16:708–716. doi: 10.1634/theoncologist.2010-0248.
    1. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:3109–3116. doi: 10.1200/JCO.2008.20.6771.
    1. Selvy M, Pereira B, Kerckhove N, Gonneau C, Feydel G, Pétorin C, et al. Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study. J Clin Med. 2020;9:2400. doi: 10.3390/jcm9082400.
    1. Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22:2261–2269. doi: 10.1007/s00520-014-2255-7.
    1. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325–3348. doi: 10.1200/JCO.20.01399.
    1. Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:1306–1319. doi: 10.1016/j.annonc.2020.07.003.
    1. Selvy M, Kerckhove N, Pereira B, Barreau F, Nguyen D, Busserolles J, et al. Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study. Front Pharmacol. 2021;12:637593. doi: 10.3389/fphar.2021.637593.
    1. André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020;21:1620–1629. doi: 10.1016/S1470-2045(20)30527-1.
    1. Lee J-H, Jeong S-K, Kim BC, Park KW, Dash A. Donepezil across the spectrum of Alzheimer’s disease: dose optimization and clinical relevance. Acta Neurol Scand. 2015;131:259–267. doi: 10.1111/ane.12386.
    1. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3:211–225.
    1. Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2007;22:806–812. doi: 10.1002/gps.1746.
    1. Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer’s disease. Br J Clin Pharmacol. 2004;58(Suppl 1):1–8. doi: 10.1111/j.1365-2125.2004.01848.x.
    1. Kawashiri T, Shimizu S, Shigematsu N, Kobayashi D, Shimazoe T. Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect. J Pharmacol Sci. 2019 doi: 10.1016/j.jphs.2019.05.009.
    1. Ferrier J, Bayet-Robert M, Dalmann R, El Guerrab A, Aissouni Y, Graveron-Demilly D, et al. Cholinergic Neurotransmission in the Posterior Insular Cortex Is Altered in Preclinical Models of Neuropathic Pain: Key Role of Muscarinic M2 Receptors in Donepezil-Induced Antinociception. J Neurosci Off J Soc Neurosci. 2015;35:16418–16430. doi: 10.1523/JNEUROSCI.1537-15.2015.
    1. Folkesson A, Honoré PH, Andersen LM, Kristensen P, Bjerrum OJ. Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies. J Neural Transm Vienna Austria. 1996;2010(117):1377–1385.
    1. Kimura M, Hayashida K, Eisenach JC, Saito S, Obata H. Relief of hypersensitivity after nerve injury from systemic donepezil involves spinal cholinergic and γ-aminobutyric acid mechanisms. Anesthesiology. 2013;118:173–180. doi: 10.1097/ALN.0b013e318277a81c.
    1. Clayton BA, Hayashida K, Childers SR, Xiao R, Eisenach JC. Oral donepezil reduces hypersensitivity after nerve injury by a spinal muscarinic receptor mechanism. Anesthesiology. 2007;106:1019–1025. doi: 10.1097/01.anes.0000265163.22007.6d.
    1. Kim SH, Kandiah N, Hsu J-L, Suthisisang C, Udommongkol C, Dash A. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer’s disease. Br J Pharmacol. 2017;174:4224–4232. doi: 10.1111/bph.14030.
    1. Gomaa AA, Makboul RM, El-Mokhtar MA, Abdel-Rahman EA, Ahmed IA, Nicola MA. Evaluation of the neuroprotective effect of donepezil in type 2 diabetic rats. Fundam Clin Pharmacol. 2020 doi: 10.1111/fcp.12585.
    1. Atef MM, El-Sayed NM, Ahmed AAM, Mostafa YM. Donepezil improves neuropathy through activation of AMPK signalling pathway in streptozotocin-induced diabetic mice. Biochem Pharmacol. 2019;159:1–10. doi: 10.1016/j.bcp.2018.11.006.
    1. Boyle Y, Fernando D, Kurz H, Miller SR, Zucchetto M, Storey J. The effect of a combination of gabapentin and donepezil in an experimental pain model in healthy volunteers: Results of a randomized controlled trial. Pain. 2014;155:2510–2516. doi: 10.1016/j.pain.2014.09.003.
    1. Kogure T, Sumitani M, Ikegami K, Abe H, Hozumi J, Inoue R, et al. Donepezil, an Acetylcholinesterase Inhibitor, Can Attenuate Gabapentinoid-Induced Somnolence in Patients with Neuropathic Pain: A Retrospective Chart Review. J Pain Palliat Care Pharmacother. 2017;31:4–9. doi: 10.1080/15360288.2017.1279500.
    1. Basnet A, Butler S, Honoré PH, Butler M, Gordh TE, Kristensen K, et al. Donepezil provides positive effects to patients treated with gabapentin for neuropathic pain: an exploratory study. Acta Anaesthesiol Scand. 2014;58:61–73. doi: 10.1111/aas.12218.
    1. Gharaei H, Shadlou H. A brief report on the efficacy of donepezil in pain management in Alzheimer’s disease. J Pain Palliat Care Pharmacother. 2014;28:37–39. doi: 10.3109/15360288.2013.876484.
    1. Bruera E, Strasser F, Shen L, Palmer JL, Willey J, Driver LC, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage. 2003;26:1049–1054. doi: 10.1016/S0885-3924(03)00332-4.
    1. LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013;37:231–239. doi: 10.1016/j.neuro.2013.05.008.
    1. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncol. 2012;14 Suppl 4:iv45–54.
    1. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82:51–77. doi: 10.1016/j.critrevonc.2011.04.012.
    1. Ferrier J, Bayet-Robert M, Pereira B, Daulhac L, Eschalier A, Pezet D, et al. A polyamine-deficient diet prevents oxaliplatin-induced acute cold and mechanical hypersensitivity in rats. PLoS ONE. 2013;8:e77828. doi: 10.1371/journal.pone.0077828.
    1. Zheng H, Xiao WH, Bennett GJ. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol. 2011;232:154–161. doi: 10.1016/j.expneurol.2011.08.016.
    1. Warwick RA, Hanani M. The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur J Pain Lond Engl. 2013;17:571–580. doi: 10.1002/j.1532-2149.2012.00219.x.
    1. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010;6:657–666. doi: 10.1038/nrneurol.2010.160.
    1. Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–1367. doi: 10.1001/jama.2013.2813.
    1. Yang Y-H, Lin J-K, Chen W-S, Lin T-C, Yang S-H, Jiang J-K, et al. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer. 2012;20:1491–1497. doi: 10.1007/s00520-011-1237-2.
    1. Uchida M, Kawazoe H, Takatori S, Namba H, Uozumi R, Tanaka A, et al. Preventive Effects of Renin-Angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy: A Retrospective Observational Study. Clin Ther. 2018 doi: 10.1016/j.clinthera.2018.05.011.
    1. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:2061–2068. doi: 10.1200/JCO.2004.08.048.
    1. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005;5:116. doi: 10.1186/1471-2407-5-116.
    1. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev . 2018;6(6):CD001190.
    1. Leyhe T, Hoffmann N, Stransky E, Laske C. Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer’s disease. Int J Neuropsychopharmacol. 2009;12:1319–1326. doi: 10.1017/S1461145709990216.
    1. Shafie A, Moradi F, Izadpanah E, Mokarizadeh A, Moloudi MR, Nikzaban M, et al. Neuroprotection of donepezil against morphine-induced apoptosis is mediated through Toll-like receptors. Eur J Pharmacol. 2015;764:292–297. doi: 10.1016/j.ejphar.2015.07.027.
    1. Papp M, Gruca P, Lason-Tyburkiewicz M, Willner P. Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats. Psychopharmacology. 2016;233:1235–1243. doi: 10.1007/s00213-016-4206-0.
    1. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer Oxf Engl. 1990;2005(41):1135–1139.
    1. Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2013;22:2787–2799. doi: 10.1007/s11136-013-0379-8.
    1. Beutler AS, Majithia N, Loprinzi CL. The past and future of “reported outcomes” in studies on chemotherapy neuropathy. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:2631–2632. doi: 10.1093/annonc/mdx520.
    1. Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, et al. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:2733–2740. doi: 10.1093/annonc/mdx491.
    1. Dorsey SG, Kleckner IR, Barton D, Mustian K, O’Mara A, St Germain D, et al. The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. J Natl Cancer Inst. 2019;111:531–537. doi: 10.1093/jnci/djz011.
    1. Alberti P, Rossi E, Cornblath DR, Merkies ISJ, Postma TJ, Frigeni B, et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2014;25:257–264. doi: 10.1093/annonc/mdt409.
    1. Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A, et al. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2017;25:3537–3544.
    1. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) Pain. 2005;114:29–36. doi: 10.1016/j.pain.2004.12.010.
    1. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248–257. doi: 10.1016/j.pain.2003.12.024.
    1. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27:26–35. doi: 10.1016/j.jmpt.2003.11.003.
    1. Bonnetain F, Fiteni F, Efficace F, Anota A. Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:1953–1956. doi: 10.1200/JCO.2014.56.7974.
    1. Geert Verbeke and Geert Molenberghs. Linear Mixed Models for Longitudinal Data. Springer Book. 2000;978-0-387-22775-7.
    1. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:1941–1967. doi: 10.1200/JCO.2013.54.0914.
    1. EMA. Clinical development of medicinal products intended for the treatment pain. European Medicines Agency. 2018. . Accessed 5 May 2022.
    1. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA. 1994;271:1609–1614. doi: 10.1001/jama.1994.03510440069036.
    1. Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain. 2012;153:1148–1158. doi: 10.1016/j.pain.2012.03.003.
    1. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014;40:872–882. doi: 10.1016/j.ctrv.2014.04.004.
    1. Cavaletti G, Tredici G, Petruccioli MG, Dondè E, Tredici P, Marmiroli P, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer Oxf Engl. 1990;2001(37):2457–2463.
    1. Renn CL, Carozzi VA, Rhee P, Gallop D, Dorsey SG, Cavaletti G. Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain. 2011;7:29. doi: 10.1186/1744-8069-7-29.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅